Maravai LifeSciences Announces August and September 2024 Investor Conference Schedule
Maravai LifeSciences (NASDAQ: MRVI), a global provider of life science reagents and services, has announced its participation in three upcoming investor conferences. CEO Trey Martin will join a panel discussion at the UBS Genomic Medicine Conference on August 14, 2024. Martin and CFO Kevin Herde will participate in fireside chats at the Wells Fargo Healthcare Conference on September 4 and the Morgan Stanley Healthcare Conference on September 5, 2024.
All presentations will be webcast live on the Maravai LifeSciences Investor Relations website, with archived versions available after the events. These conferences provide opportunities for Maravai to showcase its position in the life sciences industry and engage with investors.
Maravai LifeSciences (NASDAQ: MRVI), un fornitore globale di reagenti e servizi per le scienze della vita, ha annunciato la sua partecipazione a tre prossimi incontri con investitori. Il CEO Trey Martin parteciperà a una tavola rotonda durante il UBS Genomic Medicine Conference il 14 agosto 2024. Martin e il CFO Kevin Herde parteciperanno a conversazioni informali al Wells Fargo Healthcare Conference il 4 settembre e al Morgan Stanley Healthcare Conference il 5 settembre 2024.
Tutte le presentazioni saranno trasmesse in diretta sul sito web delle Relazioni con gli Investitori di Maravai LifeSciences, con versioni archiviate disponibili dopo gli eventi. Queste conferenze offrono opportunità a Maravai per mostrare la sua posizione nell'industria delle scienze della vita e interagire con gli investitori.
Maravai LifeSciences (NASDAQ: MRVI), un proveedor global de reactivos y servicios de ciencias de la vida, ha anunciado su participación en tres próximas conferencias para inversores. El CEO Trey Martin participará en una discusión de panel en la UBS Genomic Medicine Conference el 14 de agosto de 2024. Martin y el CFO Kevin Herde participarán en charlas informales en la Wells Fargo Healthcare Conference el 4 de septiembre y en la Morgan Stanley Healthcare Conference el 5 de septiembre de 2024.
Todas las presentaciones se transmitirán en vivo en el sitio web de Relaciones con Inversores de Maravai LifeSciences, con versiones archivadas disponibles después de los eventos. Estas conferencias brindan oportunidades a Maravai para mostrar su posición en la industria de ciencias de la vida y relacionarse con los inversores.
Maravai LifeSciences (NASDAQ: MRVI), 생명과학 시약 및 서비스를 제공하는 글로벌 회사,는 다가오는 투자자 회의에 세 번 참여할 것이라고 발표했습니다. CEO Trey Martin은 2024년 8월 14일 UBS 유전체 의학 회의에서 패널토론에 참석할 예정입니다. Martin과 CFO Kevin Herde는 2024년 9월 4일 웰스 파고 헬스케어 회의와 9월 5일 모건 스탠리 헬스케어 회의에서 대화에 참여할 예정입니다.
모든 발표는 Maravai LifeSciences의 투자자 관계 웹사이트에서 생중계되며, 이벤트 후에는 아카이브 버전을 확인할 수 있습니다. 이러한 회의는 Maravai가 생명과학 산업에서의 입지를 보여주고 투자자와 소통할 수 있는 기회를 제공합니다.
Maravai LifeSciences (NASDAQ: MRVI), un fournisseur mondial de réactifs et de services en sciences de la vie, a annoncé sa participation à trois futures conférences d’investisseurs. Le PDG Trey Martin participera à une discussion en panel lors de la UBS Genomic Medicine Conference le 14 août 2024. Martin et le CFO Kevin Herde participeront à des discussions informelles lors de la Wells Fargo Healthcare Conference le 4 septembre et de la Morgan Stanley Healthcare Conference le 5 septembre 2024.
Toutes les présentations seront diffusées en direct sur le site web des Relations Investisseurs de Maravai LifeSciences, avec des versions archivées disponibles après les événements. Ces conférences offrent à Maravai l'opportunité de mettre en avant sa position dans l'industrie des sciences de la vie et d'interagir avec les investisseurs.
Maravai LifeSciences (NASDAQ: MRVI), ein globaler Anbieter von Reagenzien und Dienstleistungen im Bereich der Lebenswissenschaften, hat seine Teilnahme an drei bevorstehenden Investorenkonferenzen bekannt gegeben. CEO Trey Martin wird am 14. August 2024 an einer Podiumsdiskussion auf der UBS Genomic Medicine Conference teilnehmen. Martin und CFO Kevin Herde werden am 4. September und 5. September 2024 an informellen Gesprächen auf der Wells Fargo Healthcare Conference und der Morgan Stanley Healthcare Conference teilnehmen.
Alle Präsentationen werden live übertragen auf der Investor Relations-Website von Maravai LifeSciences, mit archivierten Versionen, die nach den Veranstaltungen verfügbar sind. Diese Konferenzen bieten Maravai die Möglichkeit, seine Position in der Lebenswissenschaftsbranche zu präsentieren und mit Investoren in Kontakt zu treten.
- Participation in three major investor conferences, potentially increasing visibility and investor interest
- Live webcasts of presentations available, enhancing transparency and accessibility for investors
- None.
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in August and September.
On August 14, 2024, at 11:00 a.m. PDT/ 2:00 p.m. EDT, Trey Martin, Chief Executive Officer, will participate in a panel discussion of the Critical Components of the Genomic Medicine Supply Chain at the UBS Genomic Medicine Conference in Dana Point, CA.
On September 4, 2024, at 6:30 a.m. PDT/ 9:30 a.m. EDT, Trey Martin, Chief Executive Officer, and Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the Wells Fargo Healthcare Conference in Boston, MA.
On September 5, 2024, at 1:50 p.m. PDT/ 4:50 p.m. EDT, Trey Martin, Chief Executive Officer, and Kevin Herde, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley Healthcare Conference in New York, NY.
A live webcast of each presentation will be available to all interested parties on the Maravai LifeSciences Investor Relations website, under News & Events, Upcoming events. An archived version of the webcast will also be available on the Maravai website after the event is completed.
About Maravai
Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines and to support research on human diseases. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world’s leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapies companies.
For more information about Maravai LifeSciences, visit www.maravai.com.
Contact Information:
Investor Contact:
Deb Hart
Maravai LifeSciences
+1 858-988-5917
ir@maravai.com
FAQ
When is Maravai LifeSciences (MRVI) participating in the UBS Genomic Medicine Conference?
Who will represent Maravai LifeSciences (MRVI) at the Wells Fargo Healthcare Conference?
Where can investors access the webcasts of Maravai LifeSciences' (MRVI) conference presentations?
What is the date and time of Maravai LifeSciences' (MRVI) presentation at the Morgan Stanley Healthcare Conference?
